Thus, CD137 can serve as an antigen agnostic marker for T cell antigen engagement and therefore represents a better option for precise identification of T cells with superior tumor reactivity both in vitro and in vivo (24–28). The gene discussed is TNFRSF9; the disease is neoplasm.